De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Evolus Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

David Moatazedi

Algemeen directeur

US$11.2m

Totale compensatie

Percentage CEO-salaris	6.1%
Dienstverband CEO	6.4yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.9yrs
Gemiddelde ambtstermijn bestuur	6.4yrs

Recente managementupdates

Recent updates

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21

Analyse CEO-vergoeding

Hoe is David Moatazedi's beloning veranderd ten opzichte van Evolus's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$60m
Dec 31 2023	US$11m	US$688k	-US$62m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$72m
Dec 31 2022	US$4m	US$597k	-US$74m
Sep 30 2022	n/a	n/a	-US$79m
Jun 30 2022	n/a	n/a	-US$79m
Mar 31 2022	n/a	n/a	-US$71m
Dec 31 2021	US$4m	US$572k	-US$47m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$131m
Mar 31 2021	n/a	n/a	-US$137m
Dec 31 2020	US$3m	US$527k	-US$163m
Sep 30 2020	n/a	n/a	-US$67m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$99m
Dec 31 2019	US$2m	US$550k	-US$90m
Sep 30 2019	n/a	n/a	-US$88m
Jun 30 2019	n/a	n/a	-US$73m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$6m	US$362k	-US$47m

Compensatie versus markt: De totale vergoeding ($USD 11.24M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.23M ).

Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.

CEO

David Moatazedi (46 yo)

6.4yrs

Tenure

US$11,240,447

Compensatie

Mr. David Moatazedi is Independent Director at Biomerica Inc. from December 07, 2022. He has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Mo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Moatazedi	President	6.4yrs	US$11.24m	geen gegevens
Sandra Beaver	Chief Financial Officer	2.1yrs	US$2.46m	0.052% $ 559.1k
Rui Avelar	Chief Medical Officer and Head of Research & Development	10.8yrs	US$2.93m	0.31% $ 3.3m
Nareg Sagherian	Head of Global Investor Relations & Corporate Communications	less than a year	geen gegevens	geen gegevens
Jeffrey Plumer	General Counsel	no data	geen gegevens	geen gegevens
Kurt Knab	Vice President of Sales	6yrs	geen gegevens	geen gegevens
Tomoko Yamagishi-Dressler	Chief Marketing Officer	1.2yrs	geen gegevens	0.016% $ 174.1k
Jessica Novak	Senior Vice President of Human Resources	2.9yrs	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EOLS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Moatazedi	President	6.4yrs	US$11.24m	geen gegevens
David Gill	Independent Director	6.7yrs	US$256.03k	0.044% $ 468.9k
Simone Blank	Director	6.8yrs	US$235.03k	0.87% $ 9.3m
Albert White	Independent Director	less than a year	geen gegevens	geen gegevens
Vikram Malik	Chairman of the Board	6.8yrs	US$271.03k	0.37% $ 4.0m
Karah Parschauer	Independent Director	5.3yrs	US$249.03k	0.050% $ 532.7k
Brady Stewart	Independent Director	2.8yrs	US$222.03k	0.071% $ 763.9k

6.4yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EOLS wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.4 jaar).

Evolus Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee

President recently sold US$204k worth of stock

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Independent Director notifies of intention to sell stock

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

Recent updates

Evolus Continues To Make Progress

Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Evolus, Inc. Raises Financial Guidance for the Full Year of 2024

Evolus, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Evolus: Chiseling Away At The Aesthetic Market

President recently sold US$204k worth of stock

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Independent Director notifies of intention to sell stock

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold US$822k worth of stock

President notifies of intention to sell stock

New minor risk - Insider selling

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Price target increased by 12% to US$20.25

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold US$152k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Price target increased by 9.4% to US$18.11

Consensus EPS estimates fall by 46%

Price target increased by 8.4% to US$17.22

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings: EPS misses analyst expectations

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Forecast to breakeven in 2025

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Evolus: Turning That Frown Upside Down

Independent Director recently bought US$91k worth of stock

Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022

Evolus appoints Experian's exec as CFO

Consensus forecasts updated